Lit­tle vTv once again cir­cles sub­group num­ber, strug­gling to find some­thing good to say about failed Alzheimer's drug

The biotech vTv raised $117 mil­lion from their 2015 IPO $VTVT based on a pitch that they could take a failed Alzheimer’s drug from Pfiz­er and fol­low a trail of pos­i­tive sub­set da­ta to a big win. That didn’t work, with Phase A of the piv­otal pro­gram fail­ing both co-pri­ma­ry end­points re­cent­ly.

In fact, the drug arm once again did worse than a place­bo group.

But now they’ve had a chance to do some post hoc analy­sis of the first round of Phase III da­ta, and they’re back to spot­light­ing a pos­i­tive batch of da­ta for a sub­pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER